Clinical Trial: Ticagrelor Versus Clopidogrel and Eptifibatide Bolus
Study Status: Recruiting
Recruit Status: Recruiting
Study Type: Interventional
Official Title: Ticagrelor Versus Clopidogrel and Eptifibatide Bolus in Patients With Stable or Unstable Angina Undergoing Coronary Intervention: A Randomized Pharmacodynamic Study
Brief Summary: The purpose of this study is to compare the inhibition of platelet aggregation (i) ticagrelor and bivalirudin/heparin versus (ii) clopidogrel, eptifibatide and heparin in patients with unstable angina undergoing coronary intervention.
Detailed Summary:
The first 30 minutes of PCI procedure is of outmost importance when plaque ruptures and platelet activation occurs. Platelet activation and accumulation causes the formation of blood clots that may cause heart attack. As a standard of care, the doctor can prescribe medications such as are ticagrelor, eptifibatide, clopidogrel, to prevent the formation of blood clots.
100 patients with stable or unstable angina, both male and female, will be randomized to either Group A- Ticagrelor and bivalirudin/heparin or Group B- Clopidogrel, eptifibatide and heparin administrated immediately before PCI. Platelet function testing and ECG will be performed.
Sponsor: University of Alabama at Birmingham
Current Primary Outcome: Change in Platelet Function Testing [ Time Frame: 5 times (baseline, 30 min, 2 h and 4h, and 2 h) ]
Original Primary Outcome: Same as current
Current Secondary Outcome:
Original Secondary Outcome:
Information By: University of Alabama at Birmingham
Dates:
Date Received: September 27, 2016
Date Started: September 2016
Date Completion: December 2023
Last Updated: October 4, 2016
Last Verified: October 2016